RxDoctor Payments Data

Syed Ali, MD

Interventional Cardiology · Stockton, CANPI 1982997342

Payments from drug & device makers

$37,414in general payments, 2019–2025

Across 152 payments — averaging $246.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi US Services Inc.$20K
  • Medtronic$10K
  • Abbott$2K
  • Edwards Lifesciences$2K
  • Bayer$367
  • Novo Nordisk$307
  • plus $2K from 20 others

What the payments were for

  • Grants$3,33319%
  • Travel & lodging$6,73839%
  • Food & beverage$7,28942%
  • Education$540%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$37,414 in reported general payments places this provider in the 75th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$471,511
Medicare patients
701
Services billed
3,225

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban73$72,410
FarxigaDapagliflozin Propanediol37$40,888
EntrestoSacubitril/Valsartan17$12,309
Praluent PenAlirocumab16$10,454
Ezetimibe130$3,087
Atorvastatin Calcium129$1,082
Metoprolol Succinate76$889
Rosuvastatin Calcium35$687
Amiodarone Hcl11$577
Losartan Potassium45$533
Nifedipine ErNifedipine12$459
ClopidogrelClopidogrel Bisulfate34$436
Nitroglycerin22$422
Amlodipine Besylate56$346
Carvedilol51$335

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$90$72,41073 claims
AstraZenecaFarxiga$281$40,88837 claims
NovartisEntresto$39$12,30917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Stockton

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →